ID   NCI-H295R-S2
AC   CVCL_S901
SY   H295R-S2
DR   cancercelllines; CVCL_S901
DR   Wikidata; Q54908018
RX   PubMed=21924324;
RX   PubMed=22266826;
CC   Characteristics: Grows in a medium called Nu-Serum type I with a serum substitute called Ultroser-G.
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Pro (c.133T>C); ClinVar=VCV000017589; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Adrenal gland; UBERON=UBERON_0002369.
DI   NCIt; C9325; Adrenal cortex carcinoma
DI   ORDO; Orphanet_1501; Adrenocortical carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0456 ! NCI-H295
SX   Female
AG   48Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 12
//
RX   PubMed=21924324; DOI=10.1016/j.mce.2011.08.041;
RA   Wang T., Rainey W.E.;
RT   "Human adrenocortical carcinoma cell lines.";
RL   Mol. Cell. Endocrinol. 351:58-65(2012).
//
RX   PubMed=22266826; DOI=10.1055/s-0031-1298019;
RA   Wang T., Rowland J.G., Parmar J., Nesterova M., Seki T., Rainey W.E.;
RT   "Comparison of aldosterone production among human adrenocortical cell
RT   lines.";
RL   Horm. Metab. Res. 44:245-250(2012).
//